Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report

Abstract Background Portopulmonary hypertension (PPH) is a relatively rare but well-recognized complication of end-stage liver disease. Moderate or severe PPH (mean pulmonary artery pressure [mPAP] ≥ 35 mmHg) is usually a contraindication for liver transplantation due to high operation-related morta...

Descripció completa

Dades bibliogràfiques

Autors principals:	Takashi Onoe, Asuka Tanaka, Kohei Ishiyama, Kentaro Ide, Hirotaka Tashiro, Hideki Ohdan
Format:	Artigo
Idioma:	Inglês
Publicat:	Japan Surgical Society 2018-02-01
Col·lecció:	Surgical Case Reports
Matèries:	Cardiac complication Living-donor liver transplantation Phosphodiesterase type 5 inhibitor Portopulmonary hypertension
Accés en línia:	http://link.springer.com/article/10.1186/s40792-018-0423-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!